Serplulimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: First-line advanced squamous NSCLC with carboplatin and nab-paclitaxel (article dated... (EU)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also in development:Small Cell Lung Cancer · Phase 3 · investigational in the USGastric Cancer · Phase 3 · investigational in the US

Also approved (7)
EU
  • First-line advanced squamous NSCLC with carboplatin and nab-paclitaxel (article dated 2026-06-25)allsci.com
  • First-line non-squamous NSCLC (no EGFR or ALK/ROS1 mutations) with carboplatin and pemetrexed; also metastatic oesophageal squamous cell carcinomaallsci.com
  • First-line extensive-stage small cell lung cancer with carboplatin and etoposide (Hetronifly)persportaal.anp.nl
Product first approved 2025
CH
  • First-line extensive-stage small cell lung cancer with carboplatin and etoposide (Hetronifly)
Product first approved 2025swissmedic.ch
UK
  • Adults with previously untreated extensive-stage small cell lung cancer (Hetronifly)
Product first approved 2025persportaal.anp.nl
CN
  • First-line extensive-stage small cell lung cancer with carboplatin and etoposidefosunpharma.com
  • First-line unresectable locally advanced or metastatic squamous NSCLC with carboplatin and nab-paclitaxelfosunpharma.com
Product first approved 2022

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (18)
Gastric Cancer
NCT04139135 · Shanghai Henlius Biotech
2019-12-12 – 2024-10 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
NCT07739758 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-08-18 – 2030-04 · SCLC, Extensive Stage
What this study did
NCT05353257 · Shanghai Henlius Biotech
2022-05-17 – 2028-05-30 · Limited-Stage Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07177443 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-09-26 – 2035-12-31 · Locally Advanced Nasopharyngeal Carcinoma
What this study did
NCT07904156 · Sun Yat-sen University
2026-10-21 – 2032-12-30 · Non-Clear Cell Renal Cell Carcinoma (nccRCC)
What this study did
NCT07877597 · Fudan University
2026-10-15 – 2031-12-31 · Locally Advanced Colon Cancer, pMMR
What this study did
NCT07235930 · Zhejiang Cancer Hospital
2025-11-15 – 2029-07-01 · Non-Resectable Pancreas Carcinoma
What this study did
NCT07113275 · Tao Zhang
2026-05-15 – 2028-12-31 · Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy, Immunotherapy
What this study did
NCT07277842 · Sun Yat-sen University
2025-12-29 – 2028-12-29 · Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
What this study did
NCT07336953 · West China Hospital
2026-02 – 2028-07 · PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT07020247 · West China Hospital
2024-11-19 – 2028-01-31 · Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy, Anal Function Preservation
What this study did
NCT04806945 · Shanghai Henlius Biotech
2022-09-30 – 2024-10-30 · Cervical Cancer
What this study did
NCT04465734 · Shanghai Henlius Biotech
2022-11-15 – 2024-03-15 · Hepatocellular Carcinoma (HCC)
What this study did
NCT03958890 · Shanghai Henlius Biotech
2019-06-19 – 2023-12-30 · Esophageal Squamous Cell Carcinoma
What this study did
Phase 2/3 (5)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06280495 · Sun Yat-sen University
2024-02-01 – 2029-12-31 · Colorectal Cancer, Liver Metastases
What this study did
NCT07134218 · Changhai Hospital
2025-10 – 2027-10 · Rectal Cancer
What this study did
NCT04547166 · Shanghai Henlius Biotech
2021-03-10 – 2026-12-30 · Metastatic Colorectal Cancer
What this study did
Phase 2 (113)
Gastric Cancer
NCT07257575 · Guangdong Provincial People's Hospital
2025-01-05 – 2031-06-30 · Gastric Cancer Stage III
What this study did
NCT07507916 · Fudan University
2026-04-01 – 2029-12-31 · ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Adjuvant Treatment
What this study did
NCT07943533 · Shanghai Zhongshan Hospital
2026-12-01 – 2029-12-31 · HER2-Positive, Limited Metastatic, Gastric Cancer
What this study did
NCT07938021 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-12-01 – 2029-12-01 · Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC)
What this study did
NCT07872696 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-09 – 2029-09 · Gastric Neoplasms
What this study did
NCT05975749 · Fudan University
2023-01-01 – 2029-01-01 · Gastric Cancer
What this study did
NCT07933471 · Beijing Tsinghua Chang Gung Hospital
2026-08-05 – 2028-12-30 · Gastric Cancer (GC), Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
NCT07621484 · Shanghai Changzheng Hospital
2026-07-13 – 2028-05-09 · Locally Advanced Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07391826 · The First Affiliated Hospital with Nanjing Medical University
2026-02-15 – 2027-12-31 · Stage III Gastric Cancer
What this study did
NCT05311189 · Shanghai Zhongshan Hospital
2022-07-23 – 2027-12-31 · HER2-positive Gastric Cancer
What this study did
NCT06461910 · Zekuan Xu
2024-06-14 – 2027-12 · Gastric Cancer, Esophagogastric Junction Adenocarcinoma
What this study did
NCT06531291 · RenJi Hospital
2024-08-10 – 2027-08-09 · ESCC, Biliary Tract Cancer, Gastric Cancer, Pancreas Cancer
What this study did
NCT06439550 · The First Affiliated Hospital of Zhengzhou University
2024-07-15 – 2026-12-31 · HER2-positive Gastric Cancer
What this study did
NCT06576921 · Xijing Hospital
2024-11-15 – 2026-12-30 · Stomach Neoplasms, Immune Checkpoint Inhibitors
What this study did
NCT05585580 · Qilu Hospital of Shandong University
2023-03-01 – 2026-11-01 · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05769725 · RenJi Hospital
2023-03-01 – 2026-03-31 · Serplulimab,Gastric Cancer, Adjuvant Therapy
What this study did
NCT05942573 · Tianjin Medical University Cancer Institute and Hospital
2022-12-24 – 2024-12-31 · Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
NCT05246982 · Shanghai Henlius Biotech
2022-03-23 – 2024-03-30 · Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
Non-Small Cell Lung Cancer
NCT05882513 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-05-16 – 2030-12-31 · NSCLC, Neoadjuvant Therapy
What this study did
NCT07398937 · Fudan University
2026-02-05 – 2029-12-31 · Resectable Stage II-IIIa Squamous NSCLC
What this study did
NCT07253142 · Shanghai Henlius Biotech
2026-02-05 – 2028-06-19 · Non Small Cell Lung Cancer, Small Cell Lung Cancer
What this study did
NCT07064876 · Xi Junjie
2025-10 – 2027-09 · Early Lung Cancer
What this study did
NCT07596121 · Tang-Du Hospital
2026-05-13 – 2027-05-31 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT05957510 · Guangdong Association of Clinical Trials
2023-07-07 – 2026-12-31 · Small-cell Lung Cancer
What this study did
NCT05837052 · Zhejiang University
2023-05-15 – 2026-12-30 · Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT07269782 · Shanghai Henlius Biotech
2026-01-20 – 2026-11-30 · Non Small Cell Lung Cancer
What this study did
NCT05775796 · Fudan University
2023-03-15 – 2025-09-01 · Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy
What this study did
NCT06334757 · Henan Cancer Hospital
2023-05-08 – 2025-06-30 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT06195683 · Zhejiang Cancer Hospital
2023-12-01 – 2025-06-20 · Non-small Cell Lung Cancer, PDL1 Gene Mutation
What this study did
NCT04976647 · Shanghai Henlius Biotech
2022-01-18 – 2024-10-30 · Squamous Non-small-cell Lung Cancer
What this study did
NCT05675033 · Fujian Cancer Hospital
2023-01-10 – 2024-01-10 · Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor, VEGF
What this study did
Small Cell Lung Cancer
NCT06295926 · Peking Union Medical College Hospital
2024-04-04 – 2027-12-31 · Small Cell Lung Cancer
What this study did
NCT05468489 · Shanghai Henlius Biotech
2022-11-18 – 2027-12-31 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT07583511 · Sun Yat-sen University
2024-02-01 – 2027-12-01 · Small-cell Lung Cancer
What this study did
NCT06812260 · Shanghai Henlius Biotech
2025-06-24 – 2027-10-31 · SCLC, Extensive Stage
What this study did
NCT06554535 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2024-10-01 – 2027-10-01 · Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer, ECOG Performance Status Score of 0 or 1, Expected Survival ≥3 Months
What this study did
NCT05765825 · Sichuan University
2023-03-07 – 2026-12-31 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT06497530 · Guangzhou Institute of Respiratory Disease
2024-12-01 – 2026-12 · Extensive-Stage Small Cell Lung Cancer
What this study did
NCT06911606 · Guangdong Provincial People's Hospital
2024-05-22 – 2026-06-30 · SCLC, Limited Stage
What this study did
NCT05443646 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-09-23 – 2025-06-30 · Limited Stage Small Cell Lung Cancer
What this study did
NCT05354700 · Shanghai Henlius Biotech
2023-03-29 – 2024-05-29 · Small-cell Lung Cancer
What this study did
Other / comorbidity
NCT07713745 · Beijing Tiantan Hospital
2026-07-18 – 2036-12-31 · Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma, NF2-related Schwannomatosis, NF2
What this study did
NCT06850103 · First Affiliated Hospital of Zhejiang University
2025-04-22 – 2032-12 · Colorectal Carcinoma, Oligometastases, pMMR, MSS, iTNT
What this study did
NCT07772557 · The First Affiliated Hospital with Nanjing Medical University
2026-09-01 – 2032-01-20 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07381400 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2026-02-01 – 2031-12-31 · Rectal Cancer
What this study did
NCT07283692 · RenJi Hospital
2026-03-01 – 2031-09 · Triple Negative Breast Cancer
What this study did
NCT07527520 · Fudan University
2026-06 – 2031-06 · Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSS
What this study did
NCT07466303 · Xijing Hospital
2026-03-25 – 2031-04-01 · Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
What this study did
NCT07347951 · First Affiliated Hospital of Wenzhou Medical University
2025-12-01 – 2030-12-01 · Locally Advanced Rectal Cancer (LARC)
What this study did
Phase 1/2 (8)
Non-Small Cell Lung Cancer
NCT06848699 · Shanghai Henlius Biotech
2025-02-25 – 2027-10-01 · Solid Tumor Cancer, Non Small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07141771 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-12-31 – 2030-12-31 · SCLC, Extensive Stage
What this study did
NCT05882630 · Fujian Cancer Hospital
2023-06-01 – 2026-06-01 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07708285 · Beijing Tiantan Hospital
2026-07-31 – 2029-12-31 · NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, Meningioma
What this study did
NCT07175389 · West China Hospital
2026-09-01 – 2028-12-01 · Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
What this study did
NCT07358585 · Shanghai Henlius Biotech
2026-01-31 – 2028-08-23 · Colon Cancer Adenocarcinoma
What this study did
NCT05747729 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-06-21 – 2027-07-28 · Neuroendocrine Carcinoma
What this study did
NCT05501340 · Second Affiliated Hospital of Soochow University
2022-09-01 – 2024-09-01 · Malignant Ascites
What this study did
Phase 1 (9)
Small Cell Lung Cancer
NCT07231445 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-04-21 – 2028-12 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06716619 · Guangzhou FineImmune Biotechnology Co., LTD.
2025-02-13 – 2027-12-19 · Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
What this study did
NCT06115642 · Shanghai Henlius Biotech
2023-11-24 – 2027-11-30 · Advanced/Metastatic Malignant Solid Tumors
What this study did
NCT06302062 · Guangzhou FineImmune Biotechnology Co., LTD.
2023-06-06 – 2026-06-30 · Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
What this study did
NCT05483530 · Shanghai Henlius Biotech
2022-12-14 – 2025-08 · Advanced or Metastatic Solid Tumors
What this study did
NCT05400265 · Shanghai Henlius Biotech
2022-07-26 – 2024-01-31 · Adult Solid Tumor
What this study did
NCT03468751 · Henlix, Inc
2018-02-14 – 2020-08-31 · Solid Tumor
What this study did
Phase 4 (2)
Other / comorbidity
NCT06388135 · Yang Jianjun, PhD
2024-05-01 – 2027-05 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07446465 · Ye Xu
2026-03-01 – 2027-01-31 · Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
What this study did
Early phase / not applicable (6)
Gastric Cancer
NCT06128252 · Tang-Du Hospital
2024-09-01 – 2027-06-30 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06580665 · Shanghai Chest Hospital
2024-09-01 – 2030-08-11 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT06462105 · Zhou Chengzhi
2024-07-05 – 2027-06-30 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07854964 · Tang-Du Hospital
2026-10-15 – 2031-05-15 · Locally Advanced Rectal Cancer
What this study did
NCT06156332 · Shanghai Changzheng Hospital
2024-01-28 – 2027-01-28 · Advanced Solid Tumors With Neuroendocrine Differentiation
What this study did
NCT06335147 · Henan Cancer Hospital
2024-04-01 – 2026-01-31 · Metastatic Colon Cancer
What this study did
Appears in other studies (11)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (9)
Gastric Cancer
NCT07784413 · Zhejiang Cancer Hospital
2026-09-01 – 2029-07-30 · Gastric Cancer Peritoneal Metastasis (GCPM)
What this study did
Non-Small Cell Lung Cancer
NCT07418866 · Fudan University
2026-02 – 2028-12 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT05766800 · Shanghai Pulmonary Hospital, Shanghai, China
2023-03-14 – 2027-04-01 · Locally Advanced, Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
Other / comorbidity
NCT07870798 · The First Affiliated Hospital with Nanjing Medical University
2026-10-15 – 2028-12-31 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06350162 · Zhejiang Cancer Hospital
2023-10-18 – 2025-12-31 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT04297995 · Shanghai Henlius Biotech
2020-07-29 – 2025-06-30 · Head and Neck Squamous Cell Carcinoma
What this study did
Early phase / not applicable (2)
Small Cell Lung Cancer
NCT06364046 · The Central Hospital of Lishui City
2024-04-01 – 2025-12-31 · Carcinoma, Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07674342 · Tongji Hospital
2026-06-30 – 2031-06-30 · Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Gastric Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Serplulimab: this drugPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Reliable signal
NCT01170663: Overall Survival Time (OS) (Randomization up to 27.5 months): Ramucirumab (IMC-1211B) Plus Paclitaxel 9.6 months (95% CI 8.5 to 10.8) | Placebo Plus Paclitaxel 7.4 months (95% CI 6.3 to 8.4)
NCT00917384: Overall Survival (OS) (Randomization up to 28 months post-randomization): IMC-1121B (Ramucirumab) 5.2 months (95% CI 4.4 to 5.7) | Placebo 3.8 months (95% CI 2.8 to 4.7)
TislelizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabApprovedMultispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ASP2138Phase 3Multispecific antibodyClaudin 18.2 x CD3not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
ONO-4578Phase 3Small moleculeProstaglandin E2 receptor 4 (EP4)Reliable signal
NCT06256328: ONO-4578-08 study (NCT06256328): median PFS 9.0 months (ONO-4578 + nivolumab + chemotherapy) vs 6.9 months (placebo + nivolumab + chemotherapy); HR 0.67, 90% CI 0.48-0.92, P=0.040.
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signal
NCT04950322: Primary endpoint, overall survival vs placebo plus CAPOX: median 16.8 vs 10.4 months (HR 0.53) in PD-L1 CPS >=5 and 15.8 vs 11.2 months (HR 0.66) in the ITT set (JCO, 2026-09-24).
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Sonesitatug VedotinPhase 3Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
agenT-797Phase 2Cell therapyInvariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigennot yet gradedNo reviewed efficacy summary in this indication
GivastomigPhase 2Multispecific antibodyClaudin 18.2 (CLDN18.2) x 4-1BBnot yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
SHR-A1904Phase 2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
ASP546C
Phase 1/2(overall)
Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
TAK-921Phase 1/2Antibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(80 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Serplulimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (11)
December 2026 (11)
Phase 2Triple Negative Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07283692 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06497530 · CT.gov ↗
What to watch
Phase 1Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab InjectionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-19 · NCT06716619 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-28 · NCT05954429 · CT.gov ↗
What to watch
Phase 1Advanced/Metastatic Malignant Solid TumorsEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT06115642 · CT.gov ↗
What to watch
Phase 2pMMR, MSS, MSI-L, Locally Advanced Rectal CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT05731726 · CT.gov ↗
What to watch
Phase 2Malignant AscitesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06433869 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06439550 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07391826 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05311189 · CT.gov ↗
What to watch
Phase 2/3Colorectal Cancer, Liver MetastasesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06280495 · CT.gov ↗
What to watch
2027 (39)
January 2027 (3)
Phase 2Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-25 · NCT06295926 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-31 · NCT07257575 · CT.gov ↗
What to watch
Phase 4Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-31 · NCT07446465 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT06601309 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Locally Advanced Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-15 · NCT07101679 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-01 · NCT07583511 · CT.gov ↗
What to watch
Phase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT07403435 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch
Phase 2Resectable Esophageal Squamous Cell CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT07457528 · CT.gov ↗
What to watch
Early phase / not applicableSmall Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT06462105 · CT.gov ↗
What to watch
Early phase / not applicableGastric CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT06128252 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Urothelial Carcinoma, Biliary Tract Cancer, HER2RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT07506057 · CT.gov ↗
What to watch
Phase 3PDAC - Pancreatic Ductal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT07336953 · CT.gov ↗
What to watch
Phase 1/2Colon Cancer AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-28 · NCT07358585 · CT.gov ↗
What to watch
Phase 3Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy, Anal Function PreservationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-31 · NCT07020247 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT07733050 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-09 · NCT06531291 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer, Neoadjuvant TherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-31 · NCT07150949 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT07872696 · CT.gov ↗
What to watch
Phase 2Small-Cell Carcinoma of the EsophagealNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07155122 · CT.gov ↗
What to watch
Phase 2Locally Advanced Colorectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07819604 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, RelapseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-10 · NCT07604909 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2/3Rectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07134218 · CT.gov ↗
What to watch
Phase 2Rectal Cancer Patients, Locally Advanced Rectal Cancer (LARC)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-01 · NCT07898865 · CT.gov ↗
What to watch
Phase 2Non-clear Cell Renal Cell CarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-22 · NCT05831891 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Cervical CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-30 · NCT07340489 · CT.gov ↗
What to watch
December 2027 (12)
Phase 2Locally Advanced Rectal Cancer (LARC)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT07347951 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal Cancer (CRC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-15 · NCT07622550 · CT.gov ↗
What to watch
Phase 2Carcinoma of Head and/or NeckRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT06857279 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT07933471 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07398937 · CT.gov ↗
What to watch
Phase 2Colorectal Carcinoma, Oligometastases, pMMR, MSS, iTNTRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06850103 · CT.gov ↗
What to watch
Phase 2Non-Clear Cell Renal Cell CarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07488533 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed MYC/BCL2 Double-expressor DLBCLActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07538180 · CT.gov ↗
What to watch
Phase 2Locally Advanced Colorectal Cancer, Colorectal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07691632 · CT.gov ↗
What to watch
Phase 2Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal MetastasisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07902648 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07943533 · CT.gov ↗
What to watch
2028 (18)
January 2028 (2)
Phase 3Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy, ImmunotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-01 · NCT07113275 · CT.gov ↗
What to watch
Phase 2Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low ExpressionNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-09 · NCT07446049 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Rectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07381400 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07466303 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-typeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT05742425 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-01 · NCT07938021 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT06860529 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Gastric CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-09 · NCT07621484 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSSNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07 · NCT07527520 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Colorectal Cancer (Diagnosis)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-31 · NCT07134101 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1/2Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07175389 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT06580665 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-30 · NCT07699939 · CT.gov ↗
What to watch
December 2028 (5)
Phase 1Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT07231445 · CT.gov ↗
What to watch
Phase 3Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-29 · NCT07277842 · CT.gov ↗
What to watch
Phase 1/2NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, MeningiomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07708285 · CT.gov ↗
What to watch
Phase 2Rectal Neoplasms, Rectal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07543848 · CT.gov ↗
What to watch
Phase 2pMMR/MSS, Locally Advanced Rectal Carcinoma, Fasting, IntermittentNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07779694 · CT.gov ↗
What to watch
2029 (5)
May 2029 (1)
Phase 2Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05 · NCT07854977 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06 · NCT07739758 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Non-Resectable Pancreas CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07-01 · NCT07235930 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT07507916 · CT.gov ↗
What to watch
Phase 3Locally Advanced Colon Cancer, pMMRNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT07877597 · CT.gov ↗
What to watch
2030 (3)
May 2030 (1)
Early phase / not applicableLocally Advanced Rectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-05-15 · NCT07854964 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1/2Small Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06-30 · NCT07141771 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Non-Clear Cell Renal Cell Carcinoma (nccRCC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12-30 · NCT07904156 · CT.gov ↗
What to watch
2031 (2)
January 2031 (1)
Phase 2/3Non-Small Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-12-31 · NCT07772557 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 3Locally Advanced Nasopharyngeal CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2035-12-31 · NCT07177443 · CT.gov ↗
What to watch
2036 (1)
June 2036 (1)
Phase 2Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma, NF2-related Schwannomatosis, NF2Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2036-06-01 · NCT07713745 · CT.gov ↗
What to watch

See the full readout calendar ↗